- Home
- BDRX vs CVKD Comparison
BDRX vs CVKD Comparison
Compare BDRX & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- CVKD
- Stock Information
- Founded
- BDRX 2000
- CVKD 2022
- Country
- BDRX United Kingdom
- CVKD United States
- Employees
- BDRX N/A
- CVKD N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- BDRX Health Care
- CVKD Health Care
- Exchange
- BDRX Nasdaq
- CVKD Nasdaq
- Market Cap
- BDRX 2.8M
- CVKD 17.1M
- IPO Year
- BDRX N/A
- CVKD 2023
- Fundamental
- Price
- BDRX $5.98
- CVKD $15.24
- Analyst Decision
- BDRX Strong Buy
- CVKD Strong Buy
- Analyst Count
- BDRX 1
- CVKD 2
- Target Price
- BDRX $200.00
- CVKD $52.50
- AVG Volume (30 Days)
- BDRX 455.7K
- CVKD 59.6K
- Earning Date
- BDRX 10-29-2024
- CVKD 11-08-2024
- Dividend Yield
- BDRX N/A
- CVKD N/A
- EPS Growth
- BDRX N/A
- CVKD N/A
- EPS
- BDRX N/A
- CVKD N/A
- Revenue
- BDRX $104,895.00
- CVKD N/A
- Revenue This Year
- BDRX N/A
- CVKD N/A
- Revenue Next Year
- BDRX N/A
- CVKD N/A
- P/E Ratio
- BDRX N/A
- CVKD N/A
- Revenue Growth
- BDRX N/A
- CVKD N/A
- 52 Week Low
- BDRX $4.71
- CVKD $5.40
- 52 Week High
- BDRX $220.25
- CVKD $32.55
- Technical
- Relative Strength Index (RSI)
- BDRX 42.77
- CVKD 60.90
- Support Level
- BDRX $5.50
- CVKD $11.19
- Resistance Level
- BDRX $10.89
- CVKD $15.93
- Average True Range (ATR)
- BDRX 1.13
- CVKD 1.36
- MACD
- BDRX 0.31
- CVKD 0.23
- Stochastic Oscillator
- BDRX 20.55
- CVKD 61.01
About BDRX Biodexa Pharmaceuticals plc American Depositary Shs
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.